1.A Prospective, Longitudinal Study Evaluating the Efficacy of an Automated Secretion Removal Technology

The conventional method of endotracheal suctioning can lead to discomfort and adverse reactions, while a newly developed automated coughing technique for clearing secretions, although evaluated by researchers, has yet to be assessed by attending nurses in clinical settings. This article presents a prospective, longitudinal, interventional study involving 28 subjects undergoing intubation and mechanical ventilation. Following treatment for up to 7 days, the 28 subjects underwent a total of 84 procedures. The findings of this study emphasize the potential efficacy of automated artificial coughing techniques in reducing the necessity for routine endotracheal suctioning in clinical practice.

For specific details, please refer to the original text.

DOI: https://doi.org/10.4187/respcare.11584

https://rc.rcjournal.com/content/early/2024/01/31/respcare.11584

2.Surgical right pulmonary artery to left atrial shunt for severe pulmonary hypertension and bridge to lung transplantation

This article describes the case of a 38-year-old female patient diagnosed with atrial septal defect, who experienced acute hypoxic respiratory failure following childbirth. After specialist evaluation, a right pulmonary artery to left atrium shunt was performed as the preferred treatment. Bilateral lung transplantation was conducted 59 days post-surgery. The patient exhibited a successful recovery and received regular follow-up care upon discharge, enjoying a good quality of life thereafter.

For specific details, please refer to the original text.

DOI：https://doi.org/10.1016/j.xjtc.2023.12.001

https://www.jtcvstechniques.org/article/S2666-2507(23)00468-6/fulltext

3.Efficacy and safety of mepolizumab in a Chinese population with severe asthma: A Phase III, randomised, double-blind, placebo-controlled trial

Before the introduction of mepolizumab in China, omalizumab was the only approved biologic agent targeting immunoglobulin E (IgE) for the treatment of moderate to severe allergic asthma in China, and it was not indicated for the eosinophilic phenotype. The prevalence of severe asthma (SA) with eosinophilic phenotype is rising in China. This study, a Phase III randomized, double-blind, placebo-controlled trial, enrolled nearly 300 SA patients aged 12 and older. The trial demonstrated that mepolizumab provided clinical benefits to Chinese SA patients and exhibited a favorable benefit-risk profile.

For specific details, please refer to the original text.

DOI： 10.1183/23120541.00750-2023

https://openres.ersjournals.com/content/early/2024/02/08/23120541.00750-2023